← Back to Search

solifenacin succinate for Overactive Bladder

Phase 4
Waitlist Available
Led By Sanjay Mehta, M.D.
Research Sponsored by Advanced Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 16 weeks
Awards & highlights

Summary

The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.

Eligible Conditions
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline to End of Study Measured by the American Urology Association Symptom Score Questionnaire (AUASS).

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: solifenacin succinateActive Control1 Intervention
Solifenacin succinate, 5mg or 10 mg once daily
Group II: PlaceboPlacebo Group1 Intervention
Drug: Placebo oral

Find a Location

Who is running the clinical trial?

Advanced Research NetworkLead Sponsor
Astellas Pharma US, Inc.Industry Sponsor
88 Previous Clinical Trials
12,825 Total Patients Enrolled
Sanjay Mehta, M.D.Principal InvestigatorCentury Cancer Centers
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top